Characterization of Individuals with Muscular Dystrophy from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) Pilot in the United States by Hill, Bailey
Georgia State University 
ScholarWorks @ Georgia State University 
Public Health Theses School of Public Health 
Spring 5-11-2018 
Characterization of Individuals with Muscular Dystrophy from the 
Muscular Dystrophy Surveillance, Tracking, and Research Network 
(MD STARnet) Pilot in the United States 
Bailey Hill 
Follow this and additional works at: https://scholarworks.gsu.edu/iph_theses 
Recommended Citation 
Hill, Bailey, "Characterization of Individuals with Muscular Dystrophy from the Muscular Dystrophy 
Surveillance, Tracking, and Research Network (MD STARnet) Pilot in the United States." Thesis, Georgia 
State University, 2018. 
https://scholarworks.gsu.edu/iph_theses/599 
This Thesis is brought to you for free and open access by the School of Public Health at ScholarWorks @ Georgia 
State University. It has been accepted for inclusion in Public Health Theses by an authorized administrator of 




Characterization of Individuals with Muscular Dystrophy from the Muscular Dystrophy 




Bailey Melissa Hill 
 
23 April 2018 
 
 
Introduction: Because of the variability in muscular dystrophy (MD) in terms of clinical 
manifestations, affected demographic, and health trajectories, it is important to study the 
distribution of characteristics by MD type; however, few U.S. population-based studies have 
examined the distributions of sociodemographic, socioeconomic, and clinical factors across MD 
types. MD STARnet is the only U.S. population-based surveillance system for MD. To assess the 
feasibility of expanding the original surveillance methodology to other forms of MD, MDS 
conducted a pilot study, which was carried out in four sites (Arizona, Colorado, Iowa, and 12 
counties in Western New York).  
Aims: We aim to describe the demographic, sociodemographic, and clinical characteristics of 
individuals within the MD STARnet pilot cohort by MD type.  
Methods: Potential MD cases were identified through searches of clinical and administrative 
data sources using ICD-9-CM codes, ICD-10 codes, and prior MDS surveillance data. Data 
sources included medical records from inpatient and outpatient healthcare facilities, vital records, 
and hospital discharge data. Medical record abstraction of eligible cases was performed by 
trained abstractors. A total of 2,862 eligible MD cases who resided in an MDS site during the 
study period and had a health encounter were included in the pilot study. 
Results: The MD STARnet pilot cohort were primarily male, white and non-Hispanic. 
Approximately half of DBMD and DM cases had public insurance, 30-35% had private 
insurance and 8-15% had both public and private. Most MD cases were not in congregate care or 
assisted living. 27.9% of CMD patients and 22.8% of DM patients were on NIPPV. EDMD, DM 
and LGMD patients had the most frequent use of pacemakers; heart transplants were most 
frequently documented in DD, EDMD and LGMD patients. The most common medications 
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Chapter I: Introduction 
Muscular dystrophy (MD) includes heterogeneous groups of genetic muscle diseases 
characterized by progressive muscle weakness and wasting. There are nine (9) major types of 
MD: Becker MD, Duchenne MD, Congenital MD, Distal MD, Emery-Dreiffus MD, 
Facioscapulohumeral MD, Limb-Girdle MD, Myotonic Dystrophy, and Oculopharyngeal MD. 
Because Duchenne MD and Becker MD represent a spectrum of severity and are caused by 
mutations of the same gene, they are referred to in the aggregate in this study. The types of MD 
are described in further detail in Chapter II. The types of muscular dystrophy differ widely in 
affected gene, age of onset, comorbidities and disease severity, clinical interventions needed, 
health trajectories, disease outcomes, geographic distribution, and survival 1-11. Estimates of the 
crude prevalence of muscular dystrophies as a whole fall between 19.8 and 25.1/100,000 people 
12.  
Few population-based studies in the U.S. have examined the distributions of 
sociodemographic, socioeconomic, and clinical factors across muscular dystrophy types. Two 
studies have examined the risk of cancer and relative risks of other comorbidities for Myotonic 
Dystrophy patients in Utah using population-based research 3,13. However, to my knowledge, 
there are no U.S. population-based studies of individuals diagnosed with muscular dystrophies.  
To determine public health practices for targeted interventions and assess health needs, it 
is imperative that the number of people affected by muscular dystrophy, as well as the 
demographic and clinical characteristics of these individuals with different types of MD, be 
described. A description of the clinical status of persons with MD is needed to understand the 
scope of these diseases. Cross-tabulating clinical characteristics with MD type will help to 
identify areas of future research for these MD types.  
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The Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) 
is the only population-based surveillance system for MD in the U.S. and is maintained by the 
Centers for Disease Control and Prevention (CDC). From 2002-2011, MD STARnet conducted 
surveillance on Duchenne and Becker MD, using an active, multiple-sourced approach for case 
ascertainment. To assess the feasibility of expanding the methodology of Duchenne and Becker 
MD to the other forms of MD, MD STARnet funded a pilot study, which was carried out in four 
U.S. sites. This study will serve as an extension to a project currently in process that describes 
the methodology of the pilot of MD STARnet by describing the distribution of demographic, 
sociodemographic, and clinical characteristics of individuals within the MD STARnet pilot 
cohort by MD type. The MD STARnet pilot surveillance data were collected to assess the 
feasibility of extending the MD STARnet population-based surveillance protocol for Duchenne 
and Becker MD to other forms of muscular dystrophies. The MD STARnet pilot utilized a cross-
sectional design; therefore, our analyses will provide a snapshot of the distribution of 
characteristics such as employment status, mobility status, medication use, and surgeries and 
procedures in a large population with muscular dystrophy. We will describe the demographics 
(race, sex, ethnicity, age) and sociodemographic factors of persons with MD (insurance, 
employment), and infer the clinical status of persons with MD by quantifying their mobility and 
use of supportive devices (mobility, cardiac interventions, PEG (percutaneous endoscopic 







Chapter II: Literature Review 
2.1 Congenital Muscular Dystrophy 
Congenital MD is a clinically and genetically heterogeneous type of MD. The major 
subtypes of Congenital MD are collagen VI-related myopathies, laminin, alpha2-related 
muscular dystrophy, the α-dystroglycan-related MDs, lamin A/C-related MD, and selenoprotein 
N 1-related myopathy. Graziano et al. (2015) found that the most frequent subtypes of the 
disease were alpha-dystroglycan glycosylation deficiency (40.18%)14, while another study 
supported collagen VI-related myopathy as the most common subtypes of Congenital MD 15,16. 
These forms of Congenital MD vary in terms of survival, underlying genetic mechanism 
and symptoms 17-19, and researchers have described a wide spectrum of system involvement and 
prognosis for Congenital MD patients 20. Many forms of Congenital MD feature mild symptoms 
during infancy or at birth, while some forms are severe at birth and may be life-threatening in the 
first few years of life. In particular, Muntoni and Voit (2004) note that while some forms of the 
disease are severe in infants, others are more mild and survival may extend into adulthood 19. 
Hyptonia, muscle weakness, delayed walking, and mental retardation are symptoms of many 
forms of Congenital MD. Congenital MD patients typically do not have facial weakness or 
ophthalmoplegia. Cardiomyopathy rarely occurs at birth in Congenital MD patients, though this 
symptom may develop in the second decade. Night-time respiratory failure is a concern as the 
disease progresses 21. No studies have examined the health-care related cost of Congenital MD. 
Because diagnostic and genetic confirmation capacities have only begun to evolve in the 
past ten years for Congenital MD 21, epidemiologic estimates of the burden of the disease are 
limited. Individual studies have reported the prevalence of Congenital MD as 0.563/100,000 14, 
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13/100,000 and .77/100,000 22. In a systematic review, the pooled prevalence of Congenital MD 
in children was 0.82/100,000, while the pooled prevalence in adult populations was 0.99/100,000 
23. 
2.2 Duchenne and Becker Muscular Dystrophy 
Duchenne and Becker MD, X-linked disorders, almost exclusively affect males24, though 
manifesting females have been described 25. Duchenne and Becker MD are the most common 
types of MD among children 24. The mean age of diagnosis for Duchenne and Becker MD 
patients is between four and five years of age 26-28. Symptoms of Duchenne and Becker MD 
include delay and loss of motor function as well as muscle hypotonia, pain and weakness, 
cognitive delay, calf hypertrophy and cardiomyopathy and respiratory involvement 28-32. An 
earlier onset of symptoms for Duchenne and Becker MD patients is associated with an 
accelerated loss of ambulation 33. Studies have found that the mean age of ambulation loss is 
between 7 and 13 years34 with wheel-chair use by 8-14 years of age 32. Cardiomyopathy typically 
affects Duchenne MD patients between the ages of 14-15 29-31. Scoliosis and contractures may 
affect DMBD patients who use wheelchairs 32,35. The median survival for Duchenne and Becker 
MD patients has been estimated at 24 years36, with death occurring before or during the third 
decade 32. 
A prior study conducted using MD STARnet data in 2010 found that the population-
based prevalence of Duchenne and Becker MD was 1.38 /10,000 males from 5 to 24 years of age 
in six U.S. sites 37. The pooled prevalence of Duchenne and Becker MD in males globally has 
been estimated at 4.78/100,000, and the incidence of Duchenne and Becker MD ranges from 
10.7 to 27.8/100,000 people 38. Landfeldt et al. (2017) calculated the total cost of Duchenne and 
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Becker MD for the patient and caregiver at 624,240 to 713,840 EUR. This study constructed 
financial models considering the 2015 value of the Great Britain pound. 
2.3 Distal Muscular Dystrophy 
Distal MD is a rare and progressive disease featuring muscle weakness and deterioration 
of extremities, including hands, feet and lower legs. Due to the rare and highly variable nature of 
Distal MD, the prevalence of the disease is difficult to quantify, and data are limited 39,40. One 
cross-sectional study conducted in a muscle clinic in England noted that 0.9% of their MD 
population studied had Distal MD41. Another study conducted in Finland examined Tibial 
muscular dystrophy, a form of Distal MD, and found that 41 of their 60 patients were 
symptomatic 42. Though originally identified in the Finnish populations 42, TMD has since been 
identified in Italian 43, Spanish 44, French45, and Belgian 46 populations. The prevalence of some 
forms of Distal MD vary geographically 41. Though most forms of Distal MD are autosomal 
dominant, there are a few subtypes that are autosomal recessive. 
Because of the diversity of clinical characteristics, severity and age of onset for Distal 
MD, survival in these patients has not been described. Literature on Distal MD and the subtypes 
is limited; however, many forms of the disease have been identified. Muscle impairment and 
symptoms vary among these different forms. There is no evidence of cardiac or respiratory 
involvement in Laing Distal Myopathy, Miyoshi Myopathy, nor Tibial MD 40,42,47-49. However, 
cardiac and mild respiratory issues affect Distal Nebulin Myopathy patients later in disease 
progression 50. While both Miyoshi Myopathy and Tibial MD begin to manifest during the 
second or third decade of life 48,49, Laing Distal Myopathy features an early, yet variable, onset 
from 4 to 25 years of age 48,51, and Welander Distal Myopathy does not affect patients until the 





2.4 Emery-Dreiffus Muscular Dystrophy 
Emery-Dreiffus MD is characterized by a triad of clinical characteristics: contractures 
prior to significant muscle weakness; progressive, yet slow, wasting and weakness of the 
muscles with early involvement of the proximal muscle which may spread to the limb girdle 
areas; and defects in the cardiac conduction system 52. 
Emery-Dreiffus MD is classified as (1) autosomal dominant, (2) autosomal recessive, and 
(3) X-linked recessive. The underlying genetics and clinical symptoms vary among these forms 
of the disease 53-56. Cardiac involvement in the X-linked form of Emery-Dreiffus MD is more 
severe than in autosomal dominant 57. Additionally, there may be cognitive impairment in the X-
linked form, and the radiologic pattern of muscle involvement has not been established between 
X-linked and autosomal dominant Emery-Dreiffus MD 58. 
Most patients are between 3-8 years of age at the onset of symptoms, but there is a great 
variability in the age at onset. Some patients may have symptoms prior to 2 years of age, while 
others may not show symptoms until adulthood 59. Little information is available on the access to 
care for patients with Emery-Dreiffus MD, their survival rates, or healthcare-related costs. The 
pooled prevalence of Emery-Dreiffus MD in all age groups is 0.39/100,000 23. The prevalence of 
Emery-Dreiffus MD among children has only been quantified in one study, which found a 
prevalence of 0.22/100,000 60.  
2.5 Facioscapulohumeral Muscular Dystrophy 
Facioscapulohumeral MD is the third most common type of MD 61. There are two forms 
of Facioscapulohumeral MD (type 1 and type 2) that are genetically, but not clinically, 
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distinguishable 62. Though symptoms of Facioscapulohumeral MD typically first appear in the 
second decade of life, there is variability in when symptoms present; some may begin at infancy 
or before the age of 10 61,63,64. Though Facioscapulohumeral MD is a genetic disorder and 
inherited from family members, de novo mutations have been reported 63,64. The most widely 
cited prevalence of Facioscapulohumeral MD is 1/20,000 65,66. Researchers indicate that 
prevalence estimates for Facioscapulohumeral MD may vary geographically. More recently, the 
prevalence in Utah was estimated at 1/15,000, supporting the presence of a founder’s effect, 
wherein a genetic mutation in one individual is passed along to future generations, creating a 
cluster of the disease. 67. Population-based estimates of Facioscapulohumeral MD in the 
Netherlands are 12/100,000 68; in this same study, the incidence rate of Facioscapulohumeral 
MD was .3/100,000 person-years 68. Italian studies have estimated Facioscapulohumeral MD 
prevalence at 4.6/100,000 people 69,70. A systematic review found that the pooled prevalence of 
Facioscapulohumeral MD in all age groups is 3.95/100,000. The same systematic review 
calculated a pooled prevalence of 0.29/100,000 for children with Facioscapulohumeral MD 23, 
and the authors acknowledge the variability of prevalence estimates used to calculate the pooled 
measure. 
Initial muscle impairment, particularly in face, back, shoulder, humeral, trunk and leg 
muscles 61,64 characterize Facioscapulohumeral MD. Progression of this disease is variable and 
slow 61. Facial weakness is present in approximately 60% of Facioscapulohumeral MD patients, 
but the severity varies. In those Facioscapulohumeral MD patients who have facial weakness, 
25% have mild facial weakness, which may obscure the diagnosis 64. There is multisystem 
involvement in Facioscapulohumeral MD; pain and fatigue are common in Facioscapulohumeral 
MD patients 71-73. One study documented pain in 88.6% of their sample at the time the study was 
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conducted 74, and another noted at least moderate pain in over half of Facioscapulohumeral MD 
patients. Pain also appears to impact quality of life (QoL) for Facioscapulohumeral MD patients 
75. There is some evidence of cardiac abnormalities for this type of MD, including incomplete 
right bundle branch block; however cardiomyopathy is not typically present in 
Facioscapulohumeral MD patients 64,76. Respiration may also be affected in Facioscapulohumeral 
MD patients, and infrequently, hearing and vision loss may occur 61. 
2.6 Limb-Girdle Muscular Dystrophy 
Generally, Limb-Girdle MD affects the hip and shoulder girdle; however, there are 
several forms of Limb-Girdle MD, differentiated by the pattern of musculature involvement, age 
of onset, severity, and underlying genetics. In a systematic review, Mah et al. (2016) documented 
the pooled prevalence of Limb-Girdle MD as 1.63/100,000 when all age groups were considered. 
The pooled prevalence of Limb-Girdle MD in children was 0.48/100,000 23. As Mah et al. (2016) 
noted, there was heterogeneity in estimates of Limb-Girdle MD frequency in all age groups but 
not in the estimates of the frequency of Limb-Girdle MD in children 23. Limb-Girdle MD has 
been documented globally, including in Denmark 77, India 78-81, Norway 82, Mexico 83, and 
Taiwan 84 among others.  
The recessive forms of Limb-Girdle MD (LGMD2) are more common than the dominant 
forms (LGMD1)83,84; the cumulative prevalence of LGMD2 is 1/15,000 85, while dominantly 
transmitted forms of Limb-Girdle MD may only account for 10% of cases 86. Autosomal 
recessive forms of the disease are grouped into Calpainopathies, Dysferlinopathies, and 
Sarcoglycanopathies. Both Calpainopathies and Dysferlinopathies are slowly progressing and 
impact both genders in the second decade of life. Dysferlinopathies occur globally, have a distal 
or proximal onset beginning with gastrocnemius muscle impairment78. Calpainopathies are 
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characterized by proximal weakness in pelvic/shoulder girdle, joint and Achilles contractures, 
and hernias78. Sarcoglycanopathies have a childhood onset and often feature weakness of knee 
flexor 87,88. Cardiomyopathy and severe respiratory impairment has been reported in patients 
with sarcoglycanopathies 89-91. 
LGMD1B is considered a LMNA-related myopathy. Though LGMD1B has a later age of 
onset than other LMNA-related disease92, such as Emery-Dreiffus MD, the lamnopathies are 
often considered a continuum of diseases as there is significant overlap in symptoms 93. Because 
of the clinical and genetic variability of the disease, diagnosis can be challenging. 
2.7 Myotonic Dystrophy  
There are two forms of Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1) and 
Myotonic Dystrophy Type 2 (DM2), which vary in terms of age of onset, survival, and severity. 
Literature suggests that DM2 is clinically similar to DM1 but may have more mild symptoms 
and is less frequent 94. Both DM1 and DM2 involve multiple systems, including pulmonary, 
cardiac, endocrine, cognitive, sleep, and gastrointestinal dysfunction. Both DM1 and DM2 
appear to be more common in Caucasians and essentially absent in other ethnicities. Researchers 
posit that this is due to a founder’s effect of European origin. A study on an entirely Caucasian 
group in Italy found that the age-specific total prevalence for DM1 patients was 18.29/100,000 
for the 41-50 years age group whereas the 61-70 years age group of DM2 patients had the 
highest prevalence at 2.23/100,000, standardizing for age based on European population 
standards 95. In their systematic literature review, Theadom et al. (2014) noted that Myotonic 
Dystrophy is the most prevalent type of MD globally with prevalence estimates ranging from 0.5 
to 18.1/100,000 people 12. Mah et al. (2016) calculated the pooled prevalence of Myotonic 
Dystrophy in all age groups as 8.26 /100,000 and in children as 1.41/100,000 23. 
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The mean and median ages at death have been estimated at 54 and 55 years for DM1 
patients. However, 15% of the cohort used to obtain these estimates were congenital DM1 
(cDM1) patients 96. DM1 men have a higher mortality rate than DM1 women 97. QoL and Health 
Related Quality of Life are often affected in patients with DM. These individuals have been 
shown to have lower scores on all SF-36 physical health subscales compared with normative data 
98. Studies have found that lower measures of physical health are associated with fatigue, 
muscular impairment severity, psychological distress, emotional stability, lower IQ, and not 
having worked within the preceding 12 months 98. Both fatigue and the inability to do activities 
were reported as the most impactful symptoms for DM2 patients 99. DM1 patients suffering from 
fatigue and daytime sleepiness have lower QoL levels 98,100. 
2.8 Oculopharyngeal Muscular Dystrophy 
The age at onset for Oculopharyngeal MD patients is in the fifth and sixth decade 101. 
Oculopharyngeal MD is characterized by the late onset and slow progression of ptosis, 
dysphagia, and often proximal muscle weakness. In most cases ptosis or ptosis with dysphagia is 
the first symptom of Oculopharyngeal MD; however, in some cases dysphagia alone may be the 
first symptom 102. Dysphagia may lead to malnutrition and aspiration pneumonia 101,103. Other 
symptoms include weakness in axial and limb girdle muscles104, external ophthalmoplegia 105, as 
well as impairment to pelvic girdle and proximal leg muscles 106. Dysfunction of lower 
extremities influences HR-QoL for these patients 107.  
The severity and age of onset of Oculopharyngeal MD do not appear to depend on the 
size of the GCNn triplet, but this is not proven 108-114. Oculopharyngeal MD, though rare, has 
been reported globally, including France, Germany 110,115, the U.K 112, Thailand 116,117, Italy 
111,118, Bulgarian Jews 119 and a Hispanic population in New Mexico 113,120. A large cluster of 
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individuals with Oculopharyngeal MD has been documented in French-descendants in Quebec 
121. Estimates of the prevalence of Oculopharyngeal MD vary. Mazanec et al. (2013) cite studies 
that estimate the prevalence of Oculopharyngeal MD in Bukhara Jews in Israel, Quebec 
populations and French populations at 1/600, 1/1,000, and 1/200,000, respectively 122. The 
estimated prevalence of Oculopharyngeal MD in the Czech Republic 1/285,700 122, and in a 
Scottish population between 60 and 80 years of age, the prevalence of Oculopharyngeal MD has 
been estimated at 3.22/100 000 114. Though survival may not be impacted in Oculopharyngeal 





Chapter III - Methods 
3.1 MD STARnet pilot Cohort 
Individuals with MD who resided in one of the four sites for any amount of time between 
January 1, 2007 until December 31, 2011 and had at least one health encounter were included in 
this surveillance. Health encounters may have occurred in neuromuscular clinics, hospitals, or 
emergency departments. Eligible MD types included Becker MD, Congenital MD (excluding 
congenital myopathies), Duchenne MD, Distal MD, Emery-Dreiffus MD, Facioscapulohumeral 
MD, Limb-Girdle MD, DM, Oculopharyngeal MD, other MD, and MD-not otherwise specified 
(MD-NOS). For the purpose of this study, the MD-NOS/Other category is the aggregate of cases 
defined as MD-NOS, which was selected as the case definition when the type of MD was not 
specified in the medical record, and ‘other,’ which was selected when the type of MD was 
specified in the record but there was not enough evidence to confirm the accuracy of the 
diagnosis. There were no age or gender limitations for inclusion.  
3.2 Surveillance Methodology 
The United States Congress amended the Public Health Service Act in 2001 to create the 
Muscular Dystrophy Community Assistance, Research, and Education Act (MD–CARE Act),, 
which directed federal agencies to conduct research into the muscular dystrophies. The MD-
CARE Act directed CDC to conduct “epidemiological activities regarding Duchenne and other 
forms of muscular dystrophies, including collecting and analyzing information on the number, 
incidence, correlates, and symptoms of cases.” Subsequently, the CDC funded the Muscular 
Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) to conduct 
population–based surveillance of the muscular dystrophies 124. MD STARnet utilizes active 
record review with a multiple source approach. 
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From 2002-2011, MD STARnet conducted surveillance on Duchenne and Becker MD in 
the U.S. The methods of this surveillance program have been previously published (Mathews et 
al., 2010; Miller et al., 2006). Briefly, the DMBD surveillance can be segmented into four stages: 
identification of potential cases, case abstraction, clinical review and case definition and linkage 
of cases to administrative data. Trained abstractors identified individuals with ICD-9-CM code 
359.1 in hospital discharge data and identified potential cases in neuromuscular clinics from 
cases lists. Sources for Duchenne and Becker MD surveillance included: neuromuscular clinics, 
hospitals, private physician records, birth defects surveillance systems, hospital discharge data, 
vital records (birth and death), and National Death Index searches. After a potential case was 
identified at a clinic source, a trained abstractor abstracted information from medical records. For 
each potential case, a portion of the information abstracted, including clinical and family history, 
was sent to a Clinical Review Committee (CRC), which consisted of a clinician from each MD 
STARnet site. Cases were reviewed on a monthly basis. The CRC members independently 
categorized potential cases by case definition: definite, probable, possible, asymptomatic, 
female, and not Duchenne and Becker MD. If case assignment was unanimous after initial 
review of the case, then the agreed upon case definition was used. If the CRC was not unanimous 
in assigning case definition, then the case was discussed on a monthly call to come to consensus 
on the case definition. If more information was needed to determine a case definition, the case 
was sent back to the site to gather additional information. Quality control measures were used to 
logic-check values and ensure data completeness 125,126. 
3.3 MD STARnet Pilot Methods 
The MD STARnet pilot was conducted in four MD STARnet sites: Arizona (AZ), 
Colorado (CO), Iowa (IA) and a 12 counties in western New York (wNY). AZ acted as an agent 
14 
 
of the Arizona Department of Health Services to conduct MD surveillance. The IRB at the 
University of Arizona reviewed, approved, and monitored MD STARnet activities in AZ as well 
as activities at healthcare facilities where records were accessed. CO, IA, and wNY operated 
through the legal authority for public health surveillance from their respective state health 
department. At each of the four aforementioned MD STARnet sites, a data manager, program 
manager, and one to three abstractors performed surveillance activities, with oversight and input 
from a principal investigator and a neuromuscular specialist. A surveillance protocol, 
considering potential analyses, was established collaboratively between the CDC and the sites 
prior to conducting surveillance activities.  
The case-finding methodology for the MD STARnet pilot mirrored the case-finding 
methodology used by the MD STARnet for Duchenne and Becker MD surveillance. The MD 
STARnet pilot relied on case review from multiple case sources. Cases were identified in four 
ways: (1) ICD-9-CM codes [359.0, 359.1, 359.21] in medical records and administrative data; 
(2) ICD-10 codes [G71.0, G71.1] on death certificates; (3) cases from the Duchenne and Becker 
MD MD STARnet data that met criteria. The minimum criteria for case abstraction was a clinical 
diagnosis in the medical record. 
Cases were ascertained from healthcare facilities where MD patients received care and 
administrative data sources. Clinics and health care facilities providing data included 
MDA/neuromuscular clinics, hospitals, rehabilitation or physical medicine clinics, and other 
specialty clinics. Data were not obtained from other outpatients facilities due to limited time and 
resources. Specialty clinics were those that provide genetic services or other outpatient services. 
Administrative sources included birth defects registries, healthcare administrative data (including 
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accounting records), state hospital discharge summaries, Medicaid claims (in CO), and vital 
records (state birth and death certificates). 
Abstractors screened lists of ICD-9-CM and ICD-10 codes from healthcare sources and 
searched for ICD-9-CM and ICD-10 codes in administrative sources. If the abstractor identified 
an eligible case, additional information pertaining to the type of MD method of diagnosis, and 
eligibility criteria was abstracted. The method of diagnosis could be listed as clinical diagnosis, 
genetic diagnosis in self or genetic diagnosis in family. Subsequently, MD STARnet clinicians 
reviewed the abstracted data for cases in their own sites to evaluate MD type and method of 
diagnosis. If either the method of diagnosis or MD type were not clear, further review was 
executed by the CRC on a monthly basis. Using identifying and source data, abstractors 
determined if the eligible case was already included in MD STARnet’s Duchenne and Becker 
MD surveillance. If the case had been previously identified and had a more recent health 
encounter, then more recent information was abstracted and the records were linked. For each 
eligible case that had not been previously included in the MD STARnet Duchenne and Becker 
MD Surveillance, a full medical record abstraction was completed, which included core variables 
such as demographics.  
Before surveillance field activities began, sites collaboratively decided on the protocol, 
the anticipated analyses, and the data variables needed. The MD STARnet Data Coordinating 
Center (DCC) developed software to manage the collection, storage, review, and pooling of data 
as well as to conduct quality control checks, in which all abstractors were trained. Training 
included detailed instructions, presentations on each MD, practice cases and scenarios, and 
additional training for variables/conditions that were inconsistent across sites. A manual to aid in 
the structured abstraction of information was created and given to each abstractor. From the 
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lexicon of language used in MD records, equivalent terminology was developed. Abstractor 
reliability was, and a high agreement in abstraction results was reflected in the >90% Inter-rater 
Reliability (IRR) calculated prior to data. Quarterly assessments of abstraction progress and data 
quality were conducted to resolve database issues and provide targeted training.  
3.4 Variables 
Abstractors recorded the most recent information for time sensitive data from visits 
between January 1, 2007 and December 31, 2011. Time-sensitive variables included mobility, 
living situation, medication and vital status. Variables not dependent on time, such as race, 
ethnicity, and family history, were abstracted regardless of when the information was recorded 
between 2007 and 2011. Because of the epidemiological importance of race and ethnicity, 
abstraction of this information was not restricted to prior to the December 31, 2011 endpoint. 
The following demographic variables were included in this paper: type of MD (as 
described below), sex (male/female), age at start of project (January 1, 2007), race 
(white/Caucasian, black/African American, multiple/other, and unknown), and Hispanic 
ethnicity (yes/no/missing). The following sociodemographic variables were included in this 
paper: insurance status (private, public, both, uninsured/self-pay, other, not documented), living 
situation (full-time in assisted living: yes/no), and employment (as described below). The 
following clinical variables were included in this study: vital status (deceased/not deceased), age 
at death, mobility (as described below), percutaneous endoscopic gastrostomy (PEG) (yes, not 
documented), nasal intermittent positive pressure ventilation (NIPPV) (yes, not documented), 
tracheostomy (yes, not documented), cough assist (yes, not documented), pacemaker (yes, not 
documented), defibrillator (yes, not documented), and cardiac transplant (yes, not documented). 
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The count of medications at the most recent visit and the most frequently used medications at the 
most recent health encounter are also described. 
Individuals who were American Indian/Alaska Native, Asian, multiple races, Native 
Hawaiian/Pacific Islander or other were included in the multiple/other category. Hispanic 
ethnicity, regardless of race, referred to persons of Cuban, Mexican, South or Central American, 
or other Spanish culture or origin. Age at the start of the study was calculated using date of birth 
(DOB) and January 1, 2007. Participants who were born during the study had a start age of 0. 
The ages used to stratify mobility and employment were calculated using DOB and the date at 
which the variables were recorded in the medical records. 
Vital status was listed as deceased if documentation of death was available in the form of 
a death certificate, medical record, or a newspaper obituary. For deceased cases, date of death 
was recorded and the age at death was calculated using the DOB. If a case died after the 
conclusion of the study period (12/31/2011), they were considered living. 
 Individuals with an MD type of Duchenne MD or Becker MD who were female were 
reclassified as DBMD manifesting females. Male Duchenne MD and male Becker MD cases 
were combined into one category, Duchenne and Becker MD. For the purposes of this study, MD 
NOS and ‘Other’ were combined into the category MD NOS/Other. 
Employment status was included as seven dichotomous variables: younger than school 
age, student, working for pay, disabled, retired, unemployed, and not documented. For each 
individual case, more than one employment status was recorded where appropriate. Employment 
status was stratified by the age at which employment status was recorded, with the exception of 
younger than school age and not documented. Employment status was reported for the following 
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forms of MD: Duchenne and Becker MD, Facioscapulohumeral MD, Limb-Girdle MD, DM, 
Oculopharyngeal MD and MD NOS/Other.  
Mobility status reflected the patient’s mobility at the most recent health encounter prior 
to December 31, 2011. If a patient was able to ambulate with or without devices, such as 
walkers, canes, or crutches, mobility status was ‘ambulatory’. If a patient used a wheel-chair or 
stroller part-time, even if only for long distance, mobility status was ‘ambulatory with device 
support’. If a patient used a full-time manual or power wheel-chair, a full-time scooter, a full-
time unknown device, or was bedridden, mobility status was ‘non-ambulatory’. When the 
patient’s mobility did not conform to these categories or was not documented, then mobility 
status was ‘other’ or ‘not documented’. 
Clinical variables were included as ‘yes’ if they were present. An affirmative response for 
NIPPV included the use of CPAP or BiPAP. The most recent medications were abstracted from 
the cases’ most recent health encounter. A count of the medications for each individual was 
calculated from the Medications variable. Therapeutic class was assigned for the most frequently 
used medications. 
When information on a variable was not available in the medical record of an individual 
or in an administrative data set, ‘not documented’ or ‘unknown’ was indicated in the data set. 
Missing data were excluded from analyses. 
3. 5 Statistical Analyses 
Statistical Analyses were conducted in SAS 9.4, (SAS Institute, Cary NC). Means and 
standard deviations as well as median and interquartile ranges were reported for continuous 
variables. Frequencies and proportions were reported for categorical variables. Due to the rare 
nature of the muscular dystrophies, frequencies under 10 were not reported for demographic 
19 
 
variables in order to protect the privacy of subjects. Consequently, denominators for estimates 
for the total sample were adjusted according to the reportable groups of MDs. In Tables 1-7, 




Chapter IV: Results 
4.1 Demographics 
A cohort of 2,862 eligible cases was included in this study. Table 1 describes the mean 
age by MD type and provides the frequency and percent for each form of MD. The most frequent 
types of MD were Myotonic Dystrophy, Duchenne and Becker MD, and Facioscapulohumeral 
MD, which accounted for 33%, 25.5% and 9.7% of cases, respectively. The mean age at the start 
of the study was 15.5 (12.3) for Duchenne and Becker cases, while the mean age at the start of 
the study for manifesting females was 31.3 (19.6). The mean ages at the start of the study for 
Distal MD, Facioscapulohumeral MD, Limb-Girdle MD, and Myotonic Dystrophy were 43.9 
(12.6), 43.6 (20.0), 38.5 (21.8), and 38.6 (18.3). In contrast, the mean age at the start of the study 
was lower for Congenital MD cases (?̅?=13.2) and Emery-Dreiffus cases (?̅?=23.2). 
Oculopharyngeal MD cases were the oldest with a mean age at the beginning of the study period 
of 65.7 (9.8). 
Demographic and sociodemographic variables, including gender, race, Hispanic 
ethnicity, most recent insurance status and living situation, are described in Table 2. All 
demographic variables were not reported for Emery-Dreiffus MD or Distal MD cases due to the 
small number of cases. For those cases for whom demographics were reported, 36.2% were 
female and 63.7% were male as evidenced in Table 2. Table 2 further shows that 79.9% of the 
MD STARnet pilot cohort, excluding Facioscapulohumeral MD, Emery-Dreiffus MD, Distal 
MD cases, were Caucasian or white, 3.0% were black or African American, and 7.6% were in 
the Multiple/Other category. For 9.6% of cases, race was unknown. For Myotonic Dystrophy 
cases, 85.3% were white or Caucasian, and 62.6% were not Hispanic. Similarly, 78.5% of 
Duchenne and Becker MD cases were white or Caucasian, and 67.6% were not Hispanic. Thirty 
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four percent of Oculopharyngeal MD cases were Hispanic while only 26.1% were not Hispanic. 
Overall, 13.8% of cases were Hispanic, 59.5% were not Hispanic, and the Hispanic ethnicity was 
not known for 26.7% of the sample.  
4.2 Sociodemographic 
Frequencies and percentages for insurance status were not reported in Table 2 for 
individuals with Congenital MD, Distal MD, Emery-Dreiffus MD, Duchenne and Becker MD 
manifesting females, Facioscapulohumeral MD, Limb-Girdle MD, Oculopharyngeal MD and 
those classified as MD NOS/Other due to small sample sizes. 32.4% of individuals with 
Myotonic Dystrophy and males with Duchenne and Becker MD were only insured privately, 
48.8% had only public insurance, and 11.6% had both public and private insurance. 2.7% of this 
group of cases were uninsured or paid for medical costs out-of-pocket. Insurance status was not 
documented for 4.5% of Duchenne and Becker MD and Myotonic Dystrophy cases together. A 
description of the living situation was reported for Congenital MD, Myotonic Dystrophy, 
Oculopharyngeal MD and MD NOS/Other in Table 2; small cell sizes limited the analysis of 
other types of MD. Most cases were not in congregate care or assisted living (85.6%). Though 
over 80% of Myotonic Dystrophy, Oculopharyngeal MD and MD NOS/Other each were not in 
congregate care or assisted living, between 8 and 13% of these groups were not living 
independently.  
All Congenital MD, Distal MD, Emery-Dreiffus MD cases as well as all Duchenne and 
Becker MD manifesting females were excluded from analysis of employment status as there 
were not enough cases to describe patterns of employment stratified by age. Of note, it was 
possible for multiple employment status and student status entries to be made; therefore, the 
quantification of employment status for these MD types does not represent mutually exclusive 
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classification. The percentage and frequency of those who were younger than school age as well 
as the descriptive statistics for those who were students for each type of MD are provided in 
Table 3. As evidenced in Table 3, there were no Facioscapulohumeral MD, Limb-Girdle MD, or 
Oculopharyngeal MD cases younger than school age. For Duchenne and Becker MD and 
Myotonic Dystrophy cases, 2.9% and 2.7% of were younger than school age, respectively. While 
46.2% of Duchenne and Becker MD cases who were under 5 years old were students, there were 
not enough Facioscapulohumeral MD, Limb Girdle MD or Myotonic Dystrophy cases in the 
same age group who were students to report exact values. The majority of Duchenne and Becker 
MD(98.3%), Facioscapulohumeral MD (96.9%), and Limb-Girdle (95.4%) cases between the 
ages of 5 and 18 were students whereas a smaller percentage of Myotonic Dystrophy cases in the 
same age group were students (89.8%). Considering those older than 18 but younger than 35, 
41.4% of Duchenne and Becker MD and 19.2% of Myotonic Dystrophy cases were students. 
There were no Oculopharyngeal MD cases under the age of 35 who were students. 
Table 4 describes employment status for each type of MD stratified by the age at which 
the employment status was recorded. While only 13.5% of Duchenne and Becker cases between 
18 and 35 were working for pay, 32.3% between 35 and 65 were working for pay. In contrast a 
larger percentage of Facioscapulohumeral MD (47.9%), Limb-Girdle MD (49%) and Myotonic 
Dystrophy (38.3%) cases between 18 and 35 were working for pay than Facioscapulohumeral 
MD (44.6%), Limb-Girdle MD (40.5%), and Myotonic Dystrophy (25.4%) cases between 35 and 
65 years of age. While 17.8% of Duchenne and Becker cases between 18 and 35 years of age 
were disabled or unable to work, there were a larger percentage of those from 35 to 65 years of 
age who were disabled (49.2%). Duchenne and Becker cases from 35 to 65 years of age had the 
highest percentage of those who were disabled or unable to work, followed by Myotonic 
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Dystrophy cases in the same age group (45.1%). A higher percentage of Oculopharyngeal MD 
cases who were between 35 and 65 years of age were disabled compared to Oculopharyngeal 
MD cases over the age of 65. Sixty-four percent of Oculopharyngeal MD cases over 65 years-old 
were retired, and there were Duchenne and Becker cases over the age of 65 who were retired.  
4.3 Clinical Variables 
The frequency and proportion of MD cases who are ambulatory, ambulatory with device 
support, and non-ambulatory are stratified by the age which mobility status was recorded and 
reported by MD type in Table 5. The percentage of Congenital MD cases under 10 years of age 
who are ambulatory and the percentage of those who are non-ambulatory were equivalent 
(37.5%). For Congenital MD cases who are 18 to 35 years of age, 47.8% were ambulatory and 
39.1% were non-ambulatory. There were few cases with Congenital MD who were older than 
35. Most Duchenne and Becker MD under the age of 10 were ambulatory (59.4%), and 15.6% 
were ambulatory with device support. Though only 20.6% of Duchenne and Becker MD cases 
under the age of 10 were non-ambulatory, 67.7% from 10 to 18 years of age were non-
ambulatory, and 78.5% between 18 and 35 years-old were non-ambulatory. No Distal MD cases 
were under 18 years-old. Most (64.3%) of Distal MD cases from 35 to 65 years-old were 
ambulatory. For Distal MD cases in this same age group, 14.3% were ambulatory with support, 
and 21.4% were non-ambulatory. The percentage of ambulatory Emery-Dreiffus cases decreased 
as age increased, and there were no Emery-Dreiffus case who were ambulatory with device 
support. There were 3 Duchenne and Becker manifesting females between the ages of 18 and 35 
who were non-ambulatory, representing 60% of cases in this age group. 
Though 94.4% of Limb-Girdle MD cases under 10 years of age in the MD STARnet pilot 
were ambulatory and no cases in this age group were non-ambulatory, only 40% of case over 65 
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were ambulatory and 45% were non-ambulatory. For Facioscapulohumeral MD cases, 74.5% 
between 18 and 35 years of age were ambulatory. However, only 65% of Facioscapulohumeral 
MD cases between 35 and 65 were ambulatory. Comparing Facioscapulohumeral MD cases from 
35 to 65 years of age and those who are 65 years and older, the percentage of ambulatory 
Facioscapulohumeral MD cases did not change greatly. Most Myotonic Dystrophy cases from 10 
to 18 years of age (90.2%) and from 18 to 35 years of age (88.8%) were ambulatory. However, 
76.3% and 66.2% of Myotonic Dystrophy cases from 35-65 years and over 65 years were 
ambulatory, respectively. Eighty-five percent of Oculopharyngeal MD cases from 35 to 65 years 
of age were ambulatory, while only 68% of Oculopharyngeal MD cases over the age of 65 were 
ambulatory. 
The frequency and proportion of deceased cases for each type of MD are provided in 
Table 6, and the descriptive values for the age at death are provided in Table 1. The highest 
proportion of deceased cases were those with Oculopharyngeal MD (21.0%), and 
Oculopharyngeal MD cases had the highest average age at death (?̅?= 77.0). In contrast, a small 
proportion of Distal MD, Duchenne and Becker MD manifesting females, and 
Facioscapulohumeral MD were deceased. For Distal MD and Duchenne and Becker MD 
manifesting females, this low proportion may be due to the small number of cases ascertained 
and included in the cohort. Congenital MD cases had the youngest average age of death 
(?̅?=12.1). Male Duchenne and Becker MD cases, not surprisingly, had a young average age at 
death as well (?̅?=25.5).  
The frequency of PEG in Congenital MD, Distal MD, Duchenne and Becker MD, 
Duchenne and Becker MD manifesting females, Emery-Dreiffus MD, Limb-Girdle MD and MD 
NOS/Other are provided in Table 6. Approximately 21% of Congenital MD cases had a PEG 
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while no Distal MD cases received PEGs. Additionally, 9.3% of Duchenne and Becker MD 
males required a PEG. NIPPV was reported for individuals with all forms of MD except for 
Oculopharyngeal MD in Table 6. In total, 21.5% of these cases had been on NIPPV, and NIPPV 
was not documented in the records of the other 2133 cases. 27.9% of Congenital MD cases, 
32.6% of DMBD males, and 22.8% of Myotonic Dystrophy case had used some form of NIPPV. 
The frequency of cases who had ever had a tracheostomy or cough assist for Duchenne 
and Becker MD males and manifesting females as well as individuals in the MD NOS group is 
reported in Table 6. Overall, 9.1% cases had a tracheostomy documented in their records, and 
16% of cases had the use of cough assist documented in their records. Individuals in the MD 
NOS/Other group had tracheostomies (7.54%) more frequently than they used cough assist 
(0.75%). 
The use of cardiac devices and transplants are reported for individuals with Congenital 
MD, Distal MD, EDMD, Limb-Girdle MD and Myotonic Dystrophy as well as those in the MD 
NOS/Other group in Table 6. Pacemakers were noted in the records of 7.1% of cases while only 
2.6% required defibrillators. Heart transplants were required in only 10 MD cases. The use of 
pacemakers was documented for only 1 Congenital MD patient whereas 4 of 22 Emery-Dreiffus 
MD cases had pacemakers. Pacemakers were documented for 9.9% of Myotonic Dystrophy 
cases. No Distal MD cases had pacemakers, and a small percentage of Limb-Girdle MD and MD 
NOS/Other cases had pacemakers. Defibrillators were documented in 3.82% Myotonic 
Dystrophy cases. No Congenital MD or Distal MD cases had defibrillators, and only 1 Emery-
Dreiffus MD case had documented defibrillator use. Overall, there were 10 heart transplants 
documented in the 1726 cases for which this variable was reported (0.6%). Two of 17 Distal MD 
cases and 2/22 Emery-Dreiffus MD cases required heart transplants. No heart transplants were 
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documented for Congenital MD cases. Table 6 provides the frequencies and percentages of cases 
who had heart transplants for each MD type. 
. Descriptive statistics for medication counts are provided in Table 7. As a whole, MD 
cases in the MD STARnet pilot cohort had an average of 4.41 (4.47) medications listed in their 
medical record at their most recent health encounter. Oculopharyngeal MD cases had the highest 
average number of medications listed at their most recent health encounter, while Emery-
Dreiffus MD cases had the lowest average of medications. 
Table 8 described the frequency and percentage of MD cases who were taking frequently 
documented medications. Lisinopril was most frequently used by Distal MD (23.5%) and 
Duchenne and Becker MD (21.7%) cases. Approximately 9% of Oculopharyngeal MD cases 
were on Furosemide, and 6.9% of Limb Girdle cases were on Furosemide. The highest 
percentage of cases using Albuterol were Duchenne and Becker Manifesting Females (29.4%) 
and Congenital MD (14.0%) cases. Nearly 7% of Facioscapulohumeral MD cases and 7.8% of 
Duchenne and Becker cases were taking Albuterol at their most recent health encounter. The 
same percentage of Myotonic Dystrophy and Oculopharyngeal MD cases (9.2%) were taking 
Omeprazole. Duchenne and Becker MD cases were the most frequent users of Prednisone; 
19.8% of Duchenne and Becker MD cases had Prednisone documented in their record at the 
most recent health encounter.  
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Chapter V: Discussion 
5.1 Demographics 
Race and Hispanic Ethnicity 
 There is some evidence of racial and ethnic differences in MD. Though Congenital MD 
is present in many races and ethnicities 16,127, 76.74% of Congenital MD cases in the MD 
STARnet pilot cohort were white, while only 13.95% were categorized 'Multiple /Other'. Less 
than 10 cases of Congenital MD were black or African American. Unfortunately, we were unable 
to report Hispanic ethnicity for Congenital MD cases due to small cell sizes. Similarly, race and 
ethnicity could not be reported for cases of Distal MD. Literature does indicate that Distal MD 
primarily affects individuals of western European descent 42, and Distal MD has not yet been 
documented in Hispanic populations.  
Prior studies using MD STARnet Duchenne and Becker MD Surveillance data have 
found some ethnic differences in the prevalence of Duchenne and Becker MD. Romitti et al. 
(2015) found that DMBD was more common in Hispanic individuals than in black, non-Hispanic 
individuals 128. In the MD STARnet pilot surveillance data, most Duchenne and Becker MD 
cases were white or Caucasian (78.53%), and the majority of Duchenne and Becker MD cases 
were not Hispanic (67.59%), which reflects the low diversity in these surveillance sites. 
In a U.S-based study of the symptom burden of Facioscapulohumeral MD cases, most 
Facioscapulohumeral MD cases were white and non-Hispanic 129. Though we could not report 
the distribution of race for Facioscapulohumeral MD cases due to small cell sizes, it was found 
that only 7.91% of Facioscapulohumeral MD cases were of Hispanic ethnicity. The majority of 
these cases (57.19%) were not Hispanic. In terms of the influence of ethnicity, 
Facioscapulohumeral MD has also been documented in Turkish cases 130; thus further study, with 
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larger sample sizes, is needed to adequately compare the distribution of race for 
Facioscapulohumeral MD cases in the MD STARnet pilot cohort comparatively with other 
literature. 
As evidenced in Table 1, most Limb-Girdle MD cases (77.69%), Myotonic Dystrophy 
cases (85.26%) and Oculopharyngeal MD cases (63.3%) were white or Caucasian. Though 
Myotonic Dystrophy and Limb-Girdle MD cases were also primarily non-Hispanic, there were a 
higher percentage of Hispanic Oculopharyngeal MD cases than non-Hispanic Oculopharyngeal 
MD cases. Literature indicates that both DM1 and DM2 appear to be more common in 
Caucasians and essentially absent in other ethnicities, but the ethnic and racial distribution of 
Limb-Girdle MD and Oculopharyngeal MD cases are more diverse in the literature. A severe, 
childhood onset form of Limb-Girdle MD has been found in Hispanic populations in Puerto Rico 
131, and Oculopharyngeal MD has been described in a Hispanic Population in New Mexico 113,120. 
The racial distribution of Emery-Dreiffus MD is not well described and no literature has 
described Emery-Dreiffus MD in Hispanic populations. As aforementioned, Distal MD is most 
common in areas in Western Europe; however, as a result of the small number of cases of 
Emery-Dreiffus MD and Distal MD, race and Hispanic ethnicity were not reported. As a whole 




For Duchenne and Becker MD cases and Myotonic Dystrophy cases in the MD STARnet 
pilot cohort, a similar pattern of insurance status was observed. Nearly 50% of cases were 
publicly insured, between 30-35% had private insurance, and 8-15% were both publicly and 
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privately insured. The percentage of Duchenne and Becker MD and Myotonic Dystrophy cases 
who were uninsured or paid for medical expenses out of pocket was small (2-3%). The 
percentage of individuals who had insurance in the MD STARnet cohort was larger compared to 
the percent with insurance in the 2014 study conducted by Larkindale et al. 132. Using data from 
commercial insurance databases, Medicare claims, and family surveys, Larkindale et al. (2014) 
noted that 51% and 70% of Duchenne MD and Myotonic Dystrophy cases, respectively, either 
had private insurance or coverage via Medicare 132.  
Larkindale et al. (2014) also estimated a high annual cost for individual Myotonic 
Dystrophy and Duchenne MD patients ($32,236.00 and $50,952, respectively) and a high annual 
cost at a national level in the U.S. for Myotonic Dystrophy and Duchenne MD patients ( $448 
million and $787 million, respectively) 132. Because the cost of MD related medical expenses are 
high, insurance is incredibly significant to this population as costs of MD related medical 
expenses is incredibly high. Further, in a study using self-reported data from 1,057 male 
Duchenne and Becker MD patients, researchers determined that insurance status was a 
significant predictor of longer wheelchair-free survival 133. 
To my knowledge, insurance coverage for patients with Congenital MD, Distal MD, 
Emery-Dreiffus MD, Limb-Girdle MD, or Oculopharyngeal MD have not been described. Due 
to small sample sizes we were not able to describe the insurance status of these patients as well 
as Facioscapulohumeral MD patients.  
Independence and Assisted Living 
This analysis of the MD STARnet cohort revealed that most Congenital MD, Myotonic 
Dystrophy, Oculopharyngeal MD and MD NOS/other cases were not in congregate care or 
assisted living A description of the living situation of MD patients, including whether the patient 
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is in congregate or assisted living, is absent in the literature for many forms of MD. However, 
independence has been assessed through qualitative studies and by measuring Activities of Daily 
Living (ADL). 
Yamaguchi et al. (2013) conducted a qualitative study in which Duchenne and Becker 
MD patients in Japan were interviewed to ascertain their reasons for pursuing independent living. 
The researchers found that Duchenne and Becker MD patients emphasized choice, retaining 
autonomy, and improving social inclusion as the primary reasons for pursuing independent living 
134 . In another qualitative study, the use of invasive home mechanical ventilation facilitated 
independent living in Duchenne and Becker MD patients 135. This study did not describe the 
demographics of these patients. Other researchers have found that over 30% of Duchenne MD 
patients are independent in self-care, but total assistance for self-care is required between 3% and 
7% of Duchenne MD patients 136. Unfortunately, due to small cell sizes, the results of 
independent living for Duchenne and Becker MD cases could not be reported. 
In a study examining Myotonic Dystrophy patients in combination with proximal MD 
and Myopathia distalis tarda hereditaria, researchers found that over half of patients relied on 
others for activities of daily living 137. Further, Natterlund (2001) found that dependence on 
others for Myotonic Dystrophy patients increased over a 5 year period 137. Similar to the 
deterioration in Myotonic Dystrophy patients, there appears a reduction in ADL scores overtime 
for Facioscapulohumeral MD and Limb-Girdle MD patients 138,139. Though other publications 
have documented a reduction in ADL over time for Myotonic Dystrophy, Limb-Girdle MD and 
Facioscapulohumeral MD patients overtime, most of the MD STARnet cohort were not in 
congregate care or assisted living. This suggests that while daily activities and mobility may be 
reduced in individuals with MD, they are still able to live independently.  
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Future iterations of MD STARnet surveillance may collect a larger cohort of 
Facioscapulohumeral MD, Distal MD, Limb-Girdle MD, and Emery-Dreiffus MD patients 
which would enable a description of independent living for these individuals. Additionally, 
future studies with a larger number of cases may allow for an age-stratified analysis of living 
situation and analyses that examine the relationship between living situation, other clinical 
interventions and health outcomes for MD cases. 
Education 
  There were no Oculopharyngeal MD, Facioscapulohumeral MD, or Limb-Girdle MD 
cases who were younger than school age. It is likely that there were no Oculopharyngeal MD 
cases who were younger than school age or students because the typical onset of this MD is later 
than the ages for which we reported education status. It is also not surprising that a small 
percentage of Duchenne and Becker cases and Myotonic Dystrophy cases are younger than 
school age as Duchenne and Becker MD affects children and there is a congenital form of 
Myotonic Dystrophy. A smaller percentage of Myotonic Dystrophy cases between 18-35 years 
of age in the MD STARnet cohort students compared to Duchenne and Becker MD, 
Facioscapulohumeral MD, and Limb-Girdle cases of the same age group. Further a lower 
percentage of Myotonic cases compared to Duchenne and Becker MD cases between 18 and 35 
years of age were students. Though very little is known regarding the employment/education of 
the forms of MD, one study did report that 90% of Emery-Dreiffus patients who were employed 
had jobs that related to their education, supporting the significance of education for MD patients 
140. In the MD STARnet study cell sizes were too small to describe the employment and student 
status for Congenital MD, Distal MD, Emery-Dreiffus MD, and Duchenne and Becker MD 
manifesting females. Though studies have described educational attainment in patients with 
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Myotonic Dystrophy Type 1, Facioscapulohumeral MD, and Emery-Dreiffus MD, little has been 
published on education in individuals with Oculopharyngeal MD, Limb-Girdle MD, Duchenne 
and Becker MD, Distal MD and Congenital MD 141-143.  
Employment 
Almost one third of Duchenne and Becker MD cases between 35 and 65 were working 
for pay, and there were Duchenne and Becker MD cases who were over the age of 65 and retired 
in the MD STARnet cohort. These cases who are 35 and over are likely representative of the 
Becker MD cases. Other studies have supported that 73% of Becker MD patients had an 
employment history. Further, some Becker MD patients in other studies have reported that they 
ceased work due to physical disability 144. The MD STARnet cohort supports that burden of 
disability in these cases as nearly half of the Duchenne and Becker MD cases between 65 and 35 
years of age were disabled or unable to work 
The percentage of cases working for pay decreased with age for Facioscapulohumeral 
MD, LGMD, and Myotonic Dystrophy cases; however, for Duchenne and Becker MD cases, 
there was an increase in those working for pay between the 18 to <35 and 35 to <65 age groups. 
This result may be due to a shift in the make-up of the Duchenne and Becker MD group to a 
higher percentage of Becker cases. 
Though Duchenne and Becker cases from 35 to 65 years of age represented the highest 
percentage of cases disabled or unable to work, a higher percentage of Myotonic Dystrophy 
cases were disabled or unable to work compared to Limb Girdle cases and Facioscapulohumeral 
MD cases in the 35 to <65 age group, suggesting that the symptoms of Myotonic Dystrophy may 
lead to more disability in third through sixth decades of life compared to Facioscapulohumeral 
MD and Limb-Girdle patients. Interestingly, a higher percentage of Oculopharyngeal MD cases 
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who were between 35 and 65 years of age were disabled compared to Oculopharyngeal MD 
cases over the age of 65. It may be either that severely affected Oculopharyngeal MD cases do 
not survive into the sixth decade, thus making it appear as though disability may decrease with 
age for Oculopharyngeal MD cases, or that employment status was more frequently recorded as 
‘retired’ as opposed to disabled/unable to work for older cases. 
Employment trends in Duchenne MD patients are not well described as these patients 
have historically not survived past their second or third decade of life. As the life expectancy for 
Duchenne MD patients grows, researchers have emphasized the importance of transition into 
adulthood for Duchenne MD patients, including education and social activities, for QoL 145. In 
another study, 70% of Facioscapulohumeral MD patients were employed compared to 48% of 
Myotonic Dystrophy 146. Similarly, in the MD STARnet pilot cohort, a higher percentage of 
Facioscapulohumeral MD patients who were over the age of 18 were employed compared to 
Myotonic Dystrophy patients who were over the age of 18. A U.S.-based registry study found 
that approximately half of adult Myotonic Dystrophy and Facioscapulohumeral MD patients 
reported that their disease negatively impacted their employment through a variety of 
mechanisms, including earlier retirement, the need for disability and job accommodations 147, 
which was supported by the results of the MD STARnet pilot as the percentage of those who 
were disabled or unable to work increased as age increased for Myotonic Dystrophy and 
Facioscapulohumeral MD case. Future studies may compare the retirement ages of 
Facioscapulohumeral MD and Myotonic Dystrophy cases in the MD STARnet pilot to normative 
data. Additionally, because QoL and symptom burden are related to employment status for MD 
patients 98,99,148, characterizing and describing employment patterns for these individuals may 
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help to stratify MDs by risk of reduced QoL as a result of disrupted or decreased employment, 
thus identifying areas for intervention and support.  
5.3 Clinical Characteristics 
Respiratory Devices 
NIPPV 
 Diminished expiratory muscle strength can lead to pulmonary impairment and ventilator 
insufficiency in MD patients 149; however, MDs differ in the degree and pattern of respiratory 
involvement. NIPPV may prevent hypoventilation and atelectasis which may slow the 
progression of a restrictive respiratory pattern in some forms of MD 150. In the MD STARnet 
pilot cohort, NIPPV was most documented for the highest percentage of Duchenne and Becker 
MD cases, and nearly 28% of Congenital MD cases had NIPPV documented in their records. 
Though a smaller percentage of Limb Girdle MD and Myotonic Dystrophy cases comparatively 
required NIPPV, approximately 20% of these MD cases did have this respiratory intervention 
documented in their medical records. Of note, 9% of Facioscapulohumeral MD cases required 
NIPPV. 
In the MD STARnet pilot, Congenital MD cases required NIPPV frequently. Though 
Congenital MD patients appear to have impairment to non-voluntary, inspiratory muscles while 
expiratory muscles are relatively unaffected 151, only case reports have described the use of 
NIPPV in Congenital MD patients 152. Consequently, it is surprising that such a large percentage 
of Congenital MD cases in the MD STARnet pilot required NIPV. The percentage of Myotonic 
Dystrophy cases requiring NIPPV in the MD STARnet pilot cohort (22.8%) was highly 
consistent with result from other studies that determined between 25% 153 and 28% of Myotonic 
Dystrophy patients need NIV 154. 
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NIPPV were required infrequently for Emery Dreiffus MD and Distal MD cases in the 
MD STARnet pilot cohort as only 2 cases for both MDs were confirmed to have used NIPPV. 
Other studies support the infrequency of respiratory involvement in Distal and Emery Dreiffus 
MD. In a German study involving patients with a different forms of Distal MD, there was 
impairment to respiration in all patients, and no patient required NIPPV 149. Respiratory failure in 
Emery-Dreiffus MD cases may result from either weakness in the respiratory muscles or chest 
deformities 140, and some researchers have suggested that non-invasive ventilation may benefit 
Emery-Dreiffus MD patients at risk for ventilator insufficiency 155. However, the use of 
ventilator devices are not well described for Emery-Dreiffus MD in the literature.  
Though 9% of the Facioscapulohumeral MD cases in the MD STARnet pilot coort 
required NIPPV, other studies indicate that respiratory involvement is uncommon in 
Facioscapulohumeral MD patients, and the need for NIPPV is infrequent 156. Other researchers 
have found that only 1% of Facioscapulohumeral MD patients needed ventilator support 157. 
However, Wohlgemuth et al. (20117) showed that respiratory insufficiency in 
Facioscapulohumeral MD patients is related to the progression of the disease and degree of 
muscle impairment. They found no abnormalities in pulmonary function for ambulatory 
Facioscapulohumeral MD patients, and these researchers did support the presence of respiratory 
insufficiency in 1/3 of Facioscapulohumeral MD patients who were in wheelchairs 158. Similar to 
Facioscapulohumeral MD patients, the degree of respiratory involvement for Limb-Girdle MD 
patients may be related to ambulatory status; Forced Vital Capacity (FVC) for non-ambulatory 
Limb-Girdle MD is lower than FVC patients who are ambulatory 159. In this same study, the 
percentage of Limb-Girdle MD patients who required NIPPV (3/43) was lower than the 
percentage requiring NIPPV in the MD STARnet pilot cohort (17.3%) 159. Future analyses may 
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cross tabulate and examine the relationship between the use of NIPPV and ambulatory status for 
the MDs.  
Cough Assist 
The use of assisted cough devices was described only for Duchenne and Becker MD 
males and manifesting females. Approximately one fourth of Duchenne and Becker MD males 
had used Cough Assist devices, and one manifesting female used Cough Assist devices in the 
MD STARnet pilot cohort. Pneumonia, acute respiratory failure and upper-respiratory infections 
due to the retention of fluids subsequent to ineffective coughing may lead to intubation for 
Duchenne MD patients. Assisted Cough devices are recommended in order to improve airway 
clearance and reduce the risk of infection for these patients 160. The use of cough assistive 
devices had not been described for manifesting females; the use of this respiratory intervention 
likely speaks to the severity of symptoms for the manifesting female in this case. 
Tracheostomy 
Non-invasive ventilation (NIV) has been identified as an alternative to tracheostomy 161. 
Tracheostomies, a more traditional approach to manage pulmonary involvement in MD patients, 
have risks including that it may decrease cough efficiency, provoke secretions, lead to trachea 
aspiration and elevate the frequency of respiratory infections 162. There is limited contemporary 
research on tracheostomy in Myotonic Dystrophy patients. 163,164. In the MD STARnet pilot 
cohort, only 10% of Duchenne and Becker MD males had tracheostomies and only one 
Duchenne and Becker MD manifesting female (5.88%) had a tracheostomy whereas nearly 1/3 
of Duchenne and Becker MD males in the MD STARnet pilot cohort had the use of some form 
of NIPPV listed in their record. 
Cardiac Devices and Interventions 
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 Pacemakers and defibrillators 
Research indicates that Emery-Dreiffus MD, Limb-Girdle MD, and Myotonic Dystrophy 
Type 1 frequently require pacemaker implantation 165. In keeping with the literature, pacemakers 
were most frequently documented in Emery-Dreiffus MD (4 of 22), Myotonic Dystrophy (93 of 
943), and Limb-Girdle MD (10 of 260) patients in the MD STARnet pilot. Additionally, 
defibrillator use was most frequently documented in Emery-Dreiffus MD (4.55% or 1/22) and 
Myotonic Dystrophy (3.82% or 36 of 943). Though there is a bevy of information on pacemaker 
and defibrillator treatment in Myotonic Dystrophy patients 166-173, research has only begun to 
classify cardiac issues and pacemaker and defibrillator use in Emery-Dreiffus MD and Limb-
Girdle MD patients 165,174 and most of this research is limited to case reports and series 175.  
Between 3-22% of Myotonic Dystrophy patients require antiarrhythmic devices, such as 
pacemaker or cardioverter defibrillator 176. As pacemakers were documented in 9.86% of 
Myotonic Dystrophy patients and defibrillator use in 3.82% of Myotonic Dystrophy patients, the 
estimates of antiarrhythmic devices are consistent with the literature. Research indicates that the 
burden of sudden death is higher in those who have pacemakers. Due to this increased burden of 
sudden death and VT/VF in Myotonic Dystrophy patients with pacemakers, Bhakta et al. (2011) 
suggest that ICDs may be the preferred device for implantation 177; however, these authors also 
indicate that antiarrhythmic devices may not always improve the outcome, QoL, or the course of 
disease for patients, especially for those with severe impairment and high risk of non-sudden 
death 177. 
Permeant pacing has been used in Emery-Dreiffus MD and Limb-Girdle MD patients for 
AV block, atrial paralysis bradycardia, atrial standstill and atrial fibrillation 30,178,179, and 
pacemakers and ICDs have been used in Emery-Dreiffus MD patients to avoid sudden death 
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180,181. Most Emery-Dreiffus MD patients requiring cardiac devices are between 20-40 years of 
age 174,182, and studies have indicated that over 50% of Emery-Dreiffus MD patients require 
pacemaker implantations 183. However, in this analysis, 4 of 22 individuals with Emery-Dreiffus 
MD, or 18.18%, had pacemakers documented in his or her record and only 1 patient (4.55%) had 
a defibrillator documented in his or her record. Because of the small number of Emery-Dreiffus 
MD patients in the MD STARnet pilot data and because of the lack of consistency with the 
literature, this measurement may not capture the true picture of defibrillator and pacemaker use 
in this group of MD patients.  
Cardiac involvement is frequent in some forms of Limb-Girdle MD, primarily due to 
changes in the LMNA gene 184. Though studies have noted that patients with laminopathies 
frequently require pacemakers or ICDs after 30 years of age 184, the frequency of the patients 
with Limb-Girdle MD who need pacemakers has not been described, though studies have noted 
that pacemaker implantation may precede heart transplants in these patients 185. 
In this analysis, a pacemaker was only documented in the record of one of 86 Congenital 
MD patients (1.16%), and no individuals with Congenital MD had defibrillators. To our 
knowledge, only one case report has noted the use of a pacemaker in a child with Congenital MD 
186, supporting the infrequency of pacemaker and defibrillator use in this group of MD patients. 
Similarly, there was no evidence of defibrillators or pacemakers in Distal MD patients in the MD 
STARnet pilot data, and only one case report has documented the use of a pacemaker in a Distal 
MD patient 187. 
Heart Transplants 
MD patients often develop cardiomyopathy, necessitating cardiac transplantation 188. In 
the MD STARnet pilot data, heart transplantation was documented most frequently for 
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individuals with Distal MD (2/17), Emery-Dreiffus MD (2/22), and Limb-Girdle MD (4/260). Of 
note, no researchers have documented, described, or quantified the frequency of heart transplants 
in Distal MD patients.  
Case reports and series have documented cardiac transplantation in these patients 189,190, 
and one study notes that 6% of the individuals with Emery-Dreiffus MD that they studied 
required heart transplants 183. Though 9.09% of Emery-Dreiffus MD patients in the MD 
STARnet pilot cohort had heart transplants recorded in their medical records, the number of 
Emery-Dreiffus MD cases ascertained for this surveillance dataset is small. Further studies 
examining a larger number of Emery-Dreiffus MD patients would be needed to assess the 
frequency of heart transplants in this population as transplantation is the best therapy for 
cardiomyopathy in Emery-Dreiffus MD patients. However, there are very few studies on the 
efficacy and outcomes of cardiac transplant in these patients. Despite the limitations in the body 
of literature, evidence suggests cardiac transplant may be life-saving in these patients 191. In the 
single long-term study examining outcomes of heart transplant in Emery-Dreiffus MD patients, 
the researchers found that long term outcomes did not differ for Emery-Dreiffus MD and non-
Emery-Dreiffus MD patients 192.  
Similarly, cardiac involvement, frequently resulting in the need for a heart transplant, is 
characteristic of other LMNA-related myopathies, including forms of Limb-Girdle MD 92,193. 
The mean age of heart transplantation for Limb-Girdle MD was found to be 46 years 185, and 
there is not an increase of postoperative complications in Limb-Girdle MD patients who receive 
HTs compared to other HT patients 185,188. The frequency of heart transplants in Limb-Girdle 
MD is not described in the literature. 
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To our knowledge no publications report the frequency of heart transplants for 
Congenital MD patients, though one case report did document the transplant of a heart from a 
CDM patients 194; consequently, it is not surprising that no Congenital MD patients had heart 
transplants. Further, in keeping with the literature, heart transplants were infrequent in the 
Myotonic Dystrophy patients. Despite the involvement of the heart in DM, this group of MD 
patients are infrequently eligible for heart transplants because of the perioperative risk 195. 
Medications 
Lisinopril, an angiotensin converting enzyme inhibitor (ACE-I), has replaced Digoxin as 
the favored treatment for cardiomyopathy in Duchenne MD patients though some also use 
losartan, an angiotensin II receptor blocker 196. The use of Lisinopril for other MD patients has 
not been described. However, in the MD STARnet cohort, a higher percentage of Distal MD 
cases used Liniopril than Duchenne and Becker MD cases. Due to the small number of Distal 
MD cases (N=17), this result may be imprecise. Oculopharyngeal MD and Limb Girdle MD 
cases most frequently used Furosemide. Furosemide is a diuretic used in the treatment of heart 
failure, and may amplify neuromuscular blockade during anesthesia 197. Due to the cardiac 
involvement of Limb-Girdle MD, it is not surprising that approximately 7% of these cases were 
on Furosemide; however, there is no evidence of cardiac involvement in Oculopharyngeal MD 
patients. The intended use of Furosemide in Oculopharyngeal MD patients may therefore be 
different than it is for Limb Girdle MD patients. No Congenital MD, Distal MD, Duchenne and 
Becker MD manifesting females, or Emery-Dreiffus MD patients used furosemide. 
Albuterol is a beta2-adrenergic agonist. Nearly 30% of Duchenne and Becker 
Manifesting Females in the MD STARnet pilot cohort were on Albuterol. Albuterol was also 
frequently documented in the medical records of Congenital MD, Facioscapulohumeral MD, and 
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Duchenne and Becker cases at their most recent health encounters. In Facioscapulohumeral MD 
patients, Albuterol, in combination with strength training, was safe, though there was not a 
significant impact on muscle strength and volume 198. Albuterol does not change pain, fatigue or 
functional status for Facioscapulohumeral MD patients 199. Treatment with Albuterol does not 
change manual muscle testing scores for Facioscapulohumeral MD patients, the drug does 
appear to increase lean body mass as well as handgrip strength in Facioscapulohumeral MD 
patients, which suggests that the drug does have an anabolic effect 200,201. A similar increase in 
lean body mass after short-term treatment with Albuterol has been described for Duchenne and 
Becker MD patients 202. However, because of inconsistent results between a pilot trial and further 
analyses, it is unclear whether Albuterol improves function in Duchenne and Becker MD patients 
202,203. 
Omeprazole is a proton pump inhibitor that is commonly used to treat Gastroesophageal 
reflux disease (GERD) 204,205. The percentage of Myotonic Dystrophy and Oculopharyngeal MD 
cases on Omeprazole were equal in the MD STARnet pilot cohort. This suggests that GERD may 
be a burdensome symptom for both these forms of MD. Researchers found that 24% of DM1 and 
31% of DM2 patients have GERD 206, and medications for gastroesophageal reflux are used in 
22.5% of DM1 and 18.9% of DM2 patients 207. A small percentage of Duchenne and Becker MD 
cases were prescribed Omeprazole. Consistent with this modest percentage, Pane et al. (2006) 
found that while GERD may be a concern for some Duchenne and Becker MD patients, it affects 
them infrequently 208. Further, though other studies have found GERD to be a comorbidity in 
18.1% of Facioscapulohumeral MD patients studied 206, less than 6% of the Facioscapulohumeral 
MD case in the MD STARner pilot cohort were on Omeprazole.  
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Almost 20% of Duchenne and Becker MD cases had Prednisone documented in their 
record at the most recent health encounter. The use of prednisone in DMBD males has been 
previously described in studies using MD STARnet data 209,210. As Prednisone has been shown to 
improve muscle and strength, this finding is not surprising 211. 
5.4 Limitations 
Though the cross-sectional design of this study allows for a preliminary characterization 
of the population studied, there are limitations that arise as a result of surveillance methods. 
Cross-sectional study design does not enable us to study rate of progression for the MDs. 
Further, those patients who have a more rapid progression of the disease are likely to require 
healthcare more frequently than those with a slower progression of the disease in the same 
period. Thus, this pilot dataset may have more complete data for cases more severely affected by 
MD or with faster progressing forms of the disease. Additionally, less complete information may 
be available for cases who resided in an MD STARnet site but received care elsewhere. For 
examples, cases who lived near to a state border in one of the four MD STARnet sites may have 
traveled to larger neuromuscular clinic in another state, and this information would not be 
included in the pilot dataset. In comparison with patients who lived in the geographic areas for 
the entire study period, those who moved out of the areas in the first year of the study or into a 
geographic area in the concluding year of the study may have less complete information. 
Because of delays in diagnosis are common for many forms of MD, it is likely that there are 
individuals who have MD who have yet to be diagnosed in these sites.  
Using medical records as a source of data means that some data is missing or incomplete. 
Some demographic and sociodemographic information in the MD STARnet pilot data is 
incomplete, including income level, marital status, level of education, and type of occupation. As 
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a result of the incomplete data, this study provides only a preliminary and fragmented 
characterization of the MD STARnet pilot cohort. 
The most recent medications a patient took at their last health encounter during the study 
period were recorded as a free text variable and included vitamins, supplements, and over-the-
counter medications. The number of medications, and measures of central tendency and 
dispersion, include these over-the-counter medications and may distort the assessment of 
symptomatology. Further, we did not capture the history of medications. No information 
regarding the patients’ compliance, dosage, or intended use for each drug was recorded. 
Consequently, the characterization of medications does not capture the full scope of the 
medicinal management for these diseases. Longitudinal data would be needed to assess the 
progression of medications used in concordance with the progression of symptoms. Future data 
collection will feature focused collection of longitudinal data about prescription drugs for 
individuals with MD. 
In aggregating information for the classification of mobility status, important nuances 
may have been obscured. For instance, patients who were bedridden as well as patients who used 
a wheelchair full-time were classified as non-ambulatory. There are likely important quality of 
life and health-related differences in patients who are bedridden compared to those who use a 
device full-time. However, owing to the small number of cases originally classified as ‘bed-
ridden’ it was not possible to cross-tabulate this individual mobility status with the type of MD. 
Further, this variable, like employment, was stratified by the age of the patient when the mobility 
status was recorded, but this may not reflect the age at which the mobility impairment began. 
The small number of cases that were ascertained for Distal MD (N=17), Emery-Dreiffus 
MD (N=22), and Duchenne and Becker MD manifesting females (N=17) precluded reporting 
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many sociodemographic and demographic variables for these groups. Though we have provided 
a preliminary characterization of a U.S. group with muscular dystrophy, the forms of MD extend 
beyond the nine forms included in this study. Further, since the catchments from which cases 
were ascertained were not chosen randomly or to be nationally representative, the findings of this 
study are not generalizable to the entire U.S. population. 
5.5 Implications 
Though these limitations are numerous, they highlight the unique challenge of conducting 
surveillance in populations with rare diseases. The pilot dataset for the MD STARnet pilot is the 
only U.S., population-based active surveillance that exists for MD patients, and thus represents a 
cautious beginning The robust methodology for identifying and classifying cases of MD, 
including active case ascertainment, case review from a group of clinicians, and utilization of 
both medical records and administrative data, is a strength of the surveillance network. This 
study provides an important description of the various forms of MD and enhances the 
understanding of demographic and clinical characteristics of MD patients, which may help in 
identifying future research. 
Currently MD STARnet is collecting data at six U.S. sites and have improved data 
collection through lessons learned. With more data and larger cohorts, more detailed clinical and 
public health questions may be answered. Future data collection, which may include survey data, 
may seek to measure age at diagnosis and diagnostic delays for each MD Type. Future research 
may also examine the relationship between QoL and demographic/sociodemographic variables 
for patients with some MD types. Additional areas of interest include the presence of 
comorbidities and causes of death. Future studies using the MD STARnet pilot data will seek to 
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establish the minimum treated prevalence for the MDs in these six sites and compare the clinical 
interventions these patients receive to current recommendations 
This analysis not only describes the only population-based cohort of individuals with 
many forms of MD, but also informs future iterations of the MD STARnet pilot surveillance data 
collection, which would serve as the basis for studies examining the epidemiology of the MDs 
and site-specific prevalence estimates, studies on the disease progression of the MD types, 
analyses of healthcare utilizations and costs as well as studies focusing on disparities in care for 
these patients. Further, using future data, the MD STARnet pilot cohort may facilitate an analysis 
of the factors that influence health outcomes for MD patients. Population-based surveillance for 
the major forms of MD is needed to establish racial and ethnic patterns in the U.S. The MD 
STARnet pilot is currently conducting surveillance in six sites; analyses using current data may 
enable a demographic analysis. Consequently, these results serve as the basis for future studies 
that aim to identify areas for targeted interventions, lower morbidity, and describe factors that 
influence health-outcomes for MD patients. 
5.6 Conclusions 
Characterization of the MD population is important to assessing public health needs. MD 
STARnet (MDS) is the only U.S. population-based surveillance system for MD. From 2011-
2014, the MD STARnet expanded surveillance to nine MDs to test the feasibility of identifying 
individuals with childhood and adult-onset MDs. Basic demographic and clinical information 
was collected in the pilot which enabled us to characterize this population. Using multiple 
clinical and administrative data sources, the study showed it was feasible to conduct surveillance 
for other MDs. Lessons learned from the pilot have informed current methods in MD STARnet. 
This study provides an important description of the various forms of MD and enhances the 
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understanding of demographic and clinical characteristics of MD patients, which may help in 





Figure 1: Frequency of each type of MD in the MD STARnet pilot Cohort 
 
Figure 1 provides the frequencies of individuals with each form of eligible MD who were 
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Caption: Frequencies for the number of cases of each type of MD are included in Table 1. Percentages represent the proportion of the 
total MD STARnet pilot cohort. The mean age at the start of the study and the mean age at death are provided. Cases who were born 













Frequency N/% 2862 86 3.0 722 25.2 17 0.6 17 0.6 22 0.8 278 9.7 260 9.1 943 33.0 119 4.2 398 13.9
Age at 1/1/2007 Mean/SD 34.6 22.1 13.2 14.3 15.5 12.3 31.3 19.6 43.9 12.6 23.2 14.7 43.6 20.0 38.5 21.8 38.6 18.3 65.7 9.8 46.9 20.5
Age at Death Mean /SD 51.6 22.2 12.2 7.5 25.5 11.8 44.2 - 73.9 - 53.2 14.9 65.6 8.5 67.0 15.9 53.6 16.3 77.0 8.7 67.0 20.6
Myotonic OPMD















Table 2: Demographic Variables by Muscular Dystrophy Type 
 
Caption: Frequencies and percentages of demographic variables are provided for each type of MD, where possible. Note that the 
distribution of gender, race, Hispanic ethnicity, most recent insurance status, and living situation were not reportable for Emery-






n % n % n % n % n % n % n % n % n %
Female 41 47.7 0 0.0 17 0.0 117 42.1 129 49.6 470 49.8 65 54.6 187 47.0 1026 36.3
Male 45 52.3 722 0.0 0 0.0 161 57.9 131 50.4 473 50.2 54 45.4 211 53.0 1797 63.7
White/Caucasian 66 76.7 567 78.5 11 64.7 * 202 77.7 804 85.3 75 63.0 308 77.4 2033 79.9
Black/African 
American
<10 - 19 2.6 0 0.0 * 14 5.4 23 2.4 0 0.0 16 4.0 75 3.0
Multiple /Other 12 14.0 83 11.5 <10 - * 16 6.2 44 4.7 13 10.9 22 5.5 193 7.6
Unknown <10 - 53 7.3 <10 - * 28 10.8 72 7.6 31 26.1 52 13.1 244 9.6
Yes * 147 20.4 * 22 7.9 30 11.5 78 8.3 41 34.5 58 14.6 376 13.8
No * 488 67.6 * 159 57.2 143 55.0 590 62.6 31 26.1 207 52.0 1618 59.5
Unknown * 87 12.1 * 97 34.9 87 33.5 275 29.2 47 39.5 133 33.4 726 26.7
Private * 210 29.1 * * * 329 34.9 * * 539 32.4
Public * 351 48.6 * * * 462 49.0 * * 813 48.8
Both * 111 15.4 * * * 82 8.7 * * 193 11.6
Uninsured / Self-pay * 23 3.2 * * * 22 2.3 * * 45 2.7
Not documented * 27 3.7 * * * 48 5.1 * * 75 4.5
Yes <10 - * * * * 97 10.3 10 8.4 51 12.8 162 10.5
No 81 94.2 * * * * 813 86.2 98 82.4 332 83.4 1324 85.6
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Table 3: Students and Younger than School Age by Muscular Dystrophy Type 
 
The frequency and percentage of Duchenne and Becker MD, Facioscapulohumeral MD, Limb-Girdle MD, DM, Oculopharyngeal MD 
and MD NOS/Other cases who too young to be in school are provided. The frequency and percentage of those cases who are under 35 
years of age and are students are stratified by age for the same MD types. These variables, Younger than school age and Student, 
were not reportable for Congenital MD, Distal MD, Emery-Dreiffus MD, and Duchenne and Becker MD manifesting females. Where 















n % n % n % n % n % n % n %
21 2.9 0 0.00 0 0.0 25 2.7 0 0.00 * 46 2.0
0 to <5 18 46.2 <10 - <10 - <10 - 0 0 0 0.0 27 35.5
5 to <18 293 98.3 31 96.9 41 95.4 79 89.8 0 0 23 82.1 467 95.5
18 to <35 86 41.4 <10 - <10 - 32 19.2 0 0 <10 - 144 26.6
TotalMD NOS 
+ Other
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Table 4: Employment Status by Muscular Dystrophy Type 
 
The employment status of Duchenne and Becker MD, Facioscapulohumeral MD, Limb-Girdle MD, DM, Oculopharyngeal MD and 
MD NOS/Other cases are reported as frequencies and percentages. Employment status is stratified by the age at which the 
employment status was recorded. In describing those who are working for pay, disabled or unable to work, or unemployed only cases 
whose employment status was recorded when they were 18 years of age or older and younger than 65 were considered. The frequency 
and percentage of retired cases is limited to those whose employment status was recorded when they were 35 years or older. 
Employment status was not reportable for Congenital MD, Distal MD, Emery-Dreiffus MD, and Duchenne and Becker MD 
manifesting females due to small case numbers
n % n % n % n % n % n % n %
18 to <35 28 13.46 23 47.92 25 49.02 64 38.3 0 0.0 21 31.34 161 29.8
35 to <65 21 32.3 62 44.6 49 40.5 144 25.4 12 28.6 37 18.69 325 28.7
65+ <10 - <10 - <10 - <10 - <10 - <10 - 18 5.1
18 to <35 37 17.8 <10 - <10 - 30 18.0 0 0.0 15 22.4 93 17.2
35 to <65 32 49.2 39 28.1 41 33.9 256 45.1 11 26.2 84 42.4 463 40.9
65+ <10 - <10 - <10 - 19 26.4 <10 - 10 9.7 45 12.9
18 to <35 19 9.1 <10 - <10 - 23 13.8 0 0.0 14 20.9 68 12.6
35 to <65 <10 - 16 11.5 15 12.4 76 13.4 <10 - 34 17.2 154 13.6
65+ 0 0.0 <10 - <10 - <10 - <10 - <10 - 17 4.9
35 to <65 <10 - 11 7.9 <10 - 46 8.1 <10 - 20 10.1 92 8.1
65+ <10 - 30 53.6 30 75.0 44 61.1 48 64.0 67 65.1 222 63.4
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Table 5: Mobility Status by Muscular Dystrophy Type 
 
 
Mobility status is reported as the frequency and percentage for each type of MD and is stratified 
by the age at which the mobility status was recorded. Patients who do not require device 
assistance to walk are classified as ‘Ambulatory’. Those who require part-time device support 
are classified as ‘Ambulatory with Device Support,’ and patients who use a device, such as a 




n % n % n % n % n %
Ambulatory 12 37.5 5 20.8 11 47.8 3 60.0 1 50.0
Ambulatory with Device Support 4 12.5 5 20.8 2 8.7 1 20.0 0 0.0
Non-Ambulatory 12 37.5 14 58.3 9 39.1 1 20.0 1 50.0
Ambulatory 107 59.4 40 17.7 43 18.5 19 31.7 1 20.0
Ambulatory with Device Support 28 15.6 32 14.2 4 1.7 5 8.3 1 20.0
Non-Ambulatory 37 20.6 153 67.7 182 78.5 35 58.3 3 60.0
Ambulatory 1 0.0 1 50.0 2 40.0 2 57.1 2 100.0
Ambulatory with Device Support 0 0.0 1 50.0 0 0.0 1 14.3 0 0.0
Non-Ambulatory 0 0.0 0 0.0 3 60.0 1 14.3 0 0.0
Ambulatory 0 0.0 0 0.0 1 100.0 9 64.3 1 50.0
Ambulatory with Device Support 0 0.0 0 0.0 0 0.0 2 14.3 1 50.0
Non-Ambulatory 0 0.0 0 0.0 0 0.0 3 21.4 0 0.0
Ambulatory 1 100.0 5 83.3 5 62.5 4 57.1 0 0.0
Ambulatory with Device Support 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Non-Ambulatory 0 0.0 1 16.7 2 25.0 3 42.9 0 0.0
Ambulatory 6 85.7 24 92.3 35 74.5 91 65.0 37 64.9
Ambulatory with Device Support 1 14.3 0 0.0 7 14.9 11 7.9 12 21.1
Non-Ambulatory 0 0.0 1 3.9 3 6.4 33 23.6 7 12.3
Ambulatory 17 94.4 23 79.3 30 57.7 62 51.5 16 40.0
Ambulatory with Device Support 1 5.6 2 6.9 8 15.4 12 9.9 4 10.0
Non-Ambulatory 0 0.0 4 13.8 14 26.9 43 35.5 18 45.0
Ambulatory 40 70.2 55 90.2 158 88.8 425 76.3 49 66.2
Ambulatory with Device Support 1 1.8 1 1.6 5 2.8 49 8.8 10 13.5
Non-Ambulatory 3 5.3 3 4.9 6 3.4 58 10.4 12 16.2
Ambulatory 0 0.0 0 0.0 0 0.0 36 85.7 51 68.0
Ambulatory with Device Support 0 0.0 0 0.0 0 0.0 3 7.1 4 5.3
Non-Ambulatory 0 0.0 0 0.0 0 0.0 1 2.4 12 16.0
Ambulatory 6 75.0 15 71.4 46 64.8 104 53.1 46 46.5
Ambulatory with Device Support 0 0.0 1 4.8 4 5.6 15 7.7 12 12.1
Non-Ambulatory 1 12.5 5 23.8 18 25.4 56 28.6 32 32.3
Other 18 5.9 0 0.0 2 0.3 8 0.7 2 0.6





















Table 6: Clinical Interventions by Muscular Dystrophy Type 
 
The frequency and percentage of cases who had the use of the clinical interventions considered listed in their medical record were 
provided for each MD type. The percentage and frequency of those who are deceased are also provided for each type of MD. Clinical 
variables are only reported for MD types where future iterations of the MD STARnet pilot will collect data. Thus, where a variable 





n % n % n % n % n % n % n % n % n % n % n %
Vital Status Deceased 9 10.5 1 5.9 82 11.4 1 5.9 2 9.1 21 7.6 29 11.2 161 17.1 25 21.0 80 20.1 411 14.4
Yes 18 20.9 0 0.0 67 9.3 1 5.9 1 4.6 + 10 3.9 + + 35 8.8 132 8.7
Not doc. 68 79.1 17 100.0 653 90.7 16 94.1 21 95.5 + 250 96.2 + + 363 91.2 1388 91.3
Yes 24 27.9 2 11.8 235 32.6 2 11.8 2 9.1 25 9.0 45 17.3 215 22.8 + 58 14.6 608 21.5
Not doc. 62 72.1 15 88.2 485 67.4 15 88.2 20 90.9 253 91.0 215 82.7 728 77.2 + 340 85.4 2133 78.5
Yes + + 72 10.0 1 5.9 + + + + + 30 7.5 103 9.1
Not doc. + + 648 90.0 16 94.1 + + + + + 368 92.5 1032 90.9
Yes + + 178 24.7 1 5.9 + + + + + 3 0.8 182 16.0
Not doc. + + 542 75.3 16 94.1 + + + + + 395 99.3 953 84.0
Yes 1 1.2 0 0.0 + + 4 18.2 + 10 3.9 93 9.9 + 15 3.8 123 7.1
Not doc. 85 98.8 17 100.0 + + 18 81.8 + 250 96.2 850 90.1 + 383 96.2 1603 92.9
Yes 0 0.0 0 0.0 + + 1 4.6 + 3 1.2 36 3.8 + 5 1.3 45 2.6
Not doc. 86 100.0 17 100.0 + + 21 95.5 + 257 98.9 907 96.2 + 393 98.7 1681 97.4
Yes 0 0.0 2 11.8 + + 2 9.1 + 4 1.5 1 0.1 + 1 0.3 10 0.6
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Table 7: Mean and Median Medication Count at Most Recent Health Encounter 
 
Means and standard deviations are provided for the number of medications recorded in the medical records of cases at their last 
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Table 8: Distribution of the Most Frequently Documented Medications 
 
 
The most frequently recorded medications recorded in the medical record of cases at their most recent health encounter are provided. 
For each medication, the frequency and percentage of cases using the medication by MD Type are provided. 
 
n % n % n % n % n % n % n % n % n % n %
Lisinopril 4 4.7 4 23.5 157 21.7 2 11.8 2 9.1 39 14.0 36 13.8 64 6.8 17 14.3 49 12.3
Albuterol 12 14.0 0 0.0 56 7.8 5 29.4 1 4.5 19 6.8 13 5.0 75 8.0 9 7.6 37 9.3
Omeprazole 1 1.2 1 5.9 38 5.3 0 0.0 1 4.5 16 5.8 20 7.7 87 9.2 11 9.2 33 8.3
Furosemide 0 0.0 0 0.0 40 5.5 0 0.0 0 0.0 13 4.7 18 6.9 51 5.4 11 9.2 45 11.3
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